GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » COGS-to-Revenue

Q BioMed (Q BioMed) COGS-to-Revenue : 0.00 (As of Feb. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Q BioMed COGS-to-Revenue?

Q BioMed's Cost of Goods Sold for the three months ended in Feb. 2023 was $0.00 Mil. Its Revenue for the three months ended in Feb. 2023 was $0.00 Mil.

Q BioMed's COGS to Revenue for the three months ended in Feb. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Q BioMed's Gross Margin % for the three months ended in Feb. 2023 was %.

Q BioMed COGS-to-Revenue Historical Data

The historical data trend for Q BioMed's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q BioMed COGS-to-Revenue Chart

Q BioMed Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 10.87 1.26 1.03

Q BioMed Quarterly Data
May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.99 0.42 2.54 6.23 -

Q BioMed COGS-to-Revenue Calculation

Q BioMed's COGS to Revenue for the fiscal year that ended in Nov. 2022 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.293 / 0.284
=1.03

Q BioMed's COGS to Revenue for the quarter that ended in Feb. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.003 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q BioMed  (OTCPK:QBIO) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Q BioMed's Gross Margin % for the three months ended in Feb. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.003 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Q BioMed COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Q BioMed's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Q BioMed (Q BioMed) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » COGS-to-Revenue
Comparable Companies
RGMP CALA PPCB RSPI RGIN RGTPQ HGEN MYMX ATRX NMTRQ OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017
Website
https://www.qbiomed.com
Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.
Executives
William S Rosenstadt director, 10 percent owner, officer: Chief Legal Officer ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin director, 10 percent owner, officer: Chief Executive Officer 10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci director 501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay 10 percent owner 580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1